New directions for HIV vaccine development from animal models

Current Opinion in HIV and AIDS

Volumn 8, Issue 5, 2013, Pages 376-381

  McChesney, Michael B ^a   Miller, Christopher J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

animal model; HIV vaccine; mucosal transmission; nonhuman primate

Indexed keywords

ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRION; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

EID: 84883462326     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328363d3a2     Document Type: Review

References (44)

1. Kim JH, Rerks-Ngarm S, Excler JL, et al. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010; 5:428-434.
2. Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012; 490:417-420.
3. Gilbert PB, Berger JO, Stablein D, et al. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 2011; 203:969-975.
4. Morgan C, Marthas M, Miller C, et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med 2008; 5:e173.
5. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol 2008; 8:447-457.
6. Genesca M, Miller CJ. Use of nonhuman primate models to develop mucosal AIDS vaccines. Curr HIV/AIDS Rep 2010; 7:19-27.
7. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105:7552-7557.
8. Keele BF, Li H, Learn GH, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206:1117-1134.
9. Stone M, Keele BF, Ma ZM, et al. A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 2010; 84:7083-7095.
10. Ma ZM, Keele BF, Qureshi H, et al. SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in ramp-up phase plasma. AIDS Res Hum Retroviruses 2011; 27:1259-1269.
11. Miller CJ, Li Q, Abel K, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005; 79:9217-9227.
12. Stone M, Ma ZM, Genescà M, et al. Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus. Virology 2009; 392:260-270.
13. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000; 74:6087-6095.
14. Abel K, Rocke DM, Chohan B, et al. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol 2005; 79:12164-12172.
15. Li Q, Skinner PJ, Ha SJ, et al. Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science 2009; 323:1726-1729.
16. Abrahams MR, Anderson JA, Giorgi EE, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a nonpoisson distribution of transmitted variants. J Virol 2009; 83:3556-3567.
17. Genesca M, Ma ZM, Wang Y, et al. Live-attenuated lentivirus immunization modulates innate immunity and inflammation while protecting rhesus macaques from vaginal simian immunodeficiency virus challenge. J Virol 2012; 86:9188-9200. Protective immunity against vaginal SIV challenge is associated with local control of inflammation and local expansion of CD4\+ regulatory T cells.
18. Haaland RE, Hawkins PA, Salazar-Gonzalez J, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009; 5:e1000274.
19. Kearney M, Maldarelli F, Shao W, et al. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol 2009; 83:2715-2727.
20. Salazar-Gonzalez JF, Bailes E, Pham KT, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by singlegenome amplification and sequencing. J Virol 2008; 82:3952-3970.
21. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009; 206:1273-1289.
22. Liu J, Keele BF, Li H, et al. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol 2010; 84:10406-10412.
23. Ma ZM, Stone M, Piatak M Jr, et al. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol 2009; 83:3288-3297.
24. Parrish NF, Gao F, Li H, et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci USA 2013; 110:6626-6633. HIV-1 isolates from acute or chronic infection subjects were compared using several virologic and biologic parameters. Acute infection isolates were more infectious and had higher density of envelope protein.
25. Hatziioannou T, Evans DT. Animal models for HIV/AIDS research. Nat Rev Microbiol 2012; 10:852-867. This excellent review of animal models for HIV research discusses the provenance of commonly used SIV challenge virus stocks and the potential for creating molecular mixtures for virus challenge experiments.
26. Letvin NL, Rao SS, Montefiori DC, et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011; 3:81ra36.
27. Fenizia C, Keele BF, Nichols D, et al. TRIM5alpha does not affect simian immunodeficiency virus SIV(mac251) replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure. J Virol 2011; 85:12399-12409.
28. Battivelli E, Lecossier D, Matsuoka S, et al. Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. J Virol 2010; 84:11010-11019.
29. Del Prete GQ, Scarlotta M, Newman L, et al. Comparative characterization of transfection-and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J Virol 2013; 87:4584-4595. Nine commonly used SIV challenge virus stocks were compared systematically using several virologic and biologic properties. Surprisingly, transfection-derived SIVmac239 stocks were more infectious in vitro, but had much lower envelope protein density.
30. Hemelaar J. Implications of HIV diversity for the HIV-1 pandemic. J Infect 2013; 66:391-400. This recent review of the circulating clades and recombinant strains of HIV-1 of the M group that make up the global pandemic discusses how both geographic and intrahost genetic diversity contribute to the challenge of making a prophylactic vaccine.
31. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296:2354-2360.
32. Reynolds MR, Weiler AM, Weisgrau KL, et al. Macaques vaccinated with liveattenuated SIV control replication of heterologous virus. J Exp Med 2008; 205:2537-2550.
33. Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482:89-93.
34. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-1893.
35. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-1905.
36. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415:331-335.
37. Letvin NL, Huang Y, Chakrabarti BK, et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 2004; 78:7490-7497.
38. Liang X, Casimiro DR, Schleif WA, et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A-01-negative rhesus monkeys. J Virol 2005; 79: 12321-12331.
39. Casimiro DR, Cox K, Tang A, et al. Efficacy of multivalent adenovirusbased vaccine against simian immunodeficiency virus challenge. J Virol 2010; 84:2996-3003.
40. Qureshi H, Ma ZM, Huang Y, et al. Low dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus 5 then immunized with a replication defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the Phase IIb Step trial of a similar HIV-1 vaccine. J Virol 2011; 86:2239-2250.
41. Pegu P, Vaccari M, Gordon S, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol 2013; 87:1708-1719. This SIV/macaque experiment closely modelled the ALVAC prime and gp120 boost vaccine trial, demonstrating similar vaccine immunogenicity as seen in humans, but there was no significant protection from SIV acquisition following repeated, low-dose rectal SIV challenge.
42. Vaccari M, Keele BF, Bosinger SE, et al. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J Virol 2013; 87:3538-3548.
43. Barnett SW, Burke B, Sun Y, et al. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 2010; 84:5975-5985.
44. Shapiro SZ. HIV vaccine development: strategies for preclinical and clinical investigation. AIDS Res Hum Retroviruses 2013; 29; Epub ahead of print doi 10.1089/AID.2012.0337.